Lexaria Bioscience Corp.

What they do

Lexaria develops and patents DehydraTECH, a formulation and manufacturing process that combines active pharmaceutical ingredients with long-chain fatty acid-rich triglyceride oils and carrier compounds to improve oral bioavailability. The technology is used in oral suspensions, tablets, capsules, foods, beverages and oral pouches, with the company's primary focus on pharmaceutical drug products. Substantially all revenue comes from licensing DehydraTECH and from research and formulation work for third parties evaluating the technology.

Revenue drivers

• DehydraTECH licensing — Lexaria licenses its DehydraTECH technology to industry participants for use in their developmental and commercial stage products; this is the core of the business plan, covering molecules such as GLP-1/GIPs, NSAIDs, nicotine and CBD.
• R&D and B2B formulation services — The company performs small R&D projects and B2B formulation for third parties evaluating DehydraTECH for their products; total annual revenue has historically been under $1 million.
• Pharmaceutical R&D programs — Lexaria funds and runs its own preclinical and clinical studies of DehydraTECH-enhanced GLP-1, GIP, CBD and other APIs; these programs are cost centers intended to de-risk products and attract licensing partners rather than near-term revenue.

Recent performance

Annual revenue rose to $705,923 in fiscal 2025 from $464,278 in fiscal 2024, but net loss widened to $11.9 million from $5.8 million and operating cash use increased to $10.5 million from $5.0 million. Reported quarterly revenue has been uneven and minimal, at $174,000 for the quarter ended 2025-08-31, $0.00 for 2025-11-30, $20,000 for 2026-02-28 and $0.00 for 2026-05-31. As of 2026-05-31 the company reported total assets of $4.8 million, total liabilities of $437,091, shareholders' equity of $4.7 million and cash and equivalents of $3.5 million. During the nine months ended May 31, 2026, Lexaria completed final data collection for its Australian Phase 1b 12-week chronic study (GLP-1-H24-4) and announced that the study met primary endpoint objectives for safety and tolerability of DehydraTECH test articles, with clear reductions in total and gastrointestinal-specific adverse events versus the Rybelsus control arm.

Strategy

Lexaria is directing an increasing share of resources toward pharmaceutical applications, especially DehydraTECH-enhanced GLP-1 and GIP drugs for diabetes, weight loss, heart disease and hypertension. The company funded its 2024 and 2025 research programs with roughly $16 million raised through combined financing activities. It is extending its Material Transfer Agreement with a pharmaceutical partner through December 30, 2026, keeping a temporary exclusive license active while the partner reviews the full GLP-1-H26-7 pilot study dataset. Lexaria is also pursuing FDA comments on its IND for a Phase 1(b) study of DehydraTECH-CBD for hypertension, but management states it will need to raise sufficient funding or enter a collaboration to proceed.

Risks

• Dependence on licensing partners — Revenue is small and irregular, and the business plan depends on convincing industry participants to license DehydraTECH for their products.
• Failure to commercialize — The 10-K states DehydraTECH-enabled pharmaceutical products may not advance to commercialization and that setbacks in advanced trials due to lack of efficacy or safety could cause significant delays or abandonment.
• Funding requirements — Net loss was $11.9 million and operating cash use was $10.5 million in fiscal 2025, and management says it must raise funding or enter a collaboration to conduct the planned Phase 1(b) hypertension study.
• Listing-rule and key-personnel risks — The company received delisting notices in February 2026 and August 2026, and the 10-K notes its business prospects depend on a small executive team whose loss could impede execution.

Outlook

Management highlights completed data collection and positive safety and tolerability findings from its Australian Phase 1b chronic study of DehydraTECH-CBD, semaglutide and tirzepatide, and says data for the 12-week chronic human trial report is being analyzed. It is progressing FDA comments on its IND for a Phase 1(b) DehydraTECH-CBD hypertension study but needs funding or a collaboration before proceeding. The extended MTA with PharmaCO through December 30, 2026 keeps a temporary exclusive license in force while the partner reviews the GLP-1-H26-7 pilot study dataset.